Literature DB >> 17123821

Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.

Yu Mi Ahn1, Lakshminarayana Vogeti, Chun-Jing Liu, Hari K R Santhapuram, Jonathan M White, Veena Vasandani, Lester A Mitscher, Gerald H Lushington, Paul R Hanson, Douglas R Powell, Richard H Himes, Katherine F Roby, Qizhuang Ye, Gunda I Georg.   

Abstract

The design and synthesis of a small library of 8-amidoflavone, 8-sulfonamidoflavone, 8-amido-7-hydroxyflavone, and heterocyclic analogues of flavopiridol is reported. The potential activity of these compounds as kinase inhibitors was evaluated by cytotoxicity studies in MCF-7 and ID-8 cancer cell lines and inhibition of CDK2-Cyclin A enzyme activity in vitro. The antiproliferative and CDK2-Cyclin A inhibitory activity of these analogues was significantly lower than the activity of flavopiridol. Molecular docking simulations were carried out and these studies suggested a different binding orientation inside the CDK2 binding pocket for these analogues compared to flavopiridol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123821      PMCID: PMC1876666          DOI: 10.1016/j.bmc.2006.10.063

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  35 in total

1.  Kinase inhibitors: not just for kinases anymore.

Authors:  Susan L McGovern; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 3.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

4.  Structural basis for chemical inhibition of CDK2.

Authors:  S H Kim; U Schulze-Gahmen; J Brandsen; W F de Azevedo Júnior
Journal:  Prog Cell Cycle Res       Date:  1996

5.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

Authors:  W F De Azevedo; H J Mueller-Dieckmann; U Schulze-Gahmen; P J Worland; E Sausville; S H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

6.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Authors:  B A Carlson; M M Dubay; E A Sausville; L Brizuela; P J Worland
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

7.  Inhibition of CDKs as a therapeutic modality.

Authors:  E A Sausville; J Johnson; M Alley; D Zaharevitz; A M Senderowicz
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

8.  Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

Authors:  H Sedlacek; J Czech; R Naik; G Kaur; P Worland; M Losiewicz; B Parker; B Carlson; A Smith; A Senderowicz; E Sausville
Journal:  Int J Oncol       Date:  1996-12       Impact factor: 5.650

9.  Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

Authors:  P M Fischer; D P Lane
Journal:  Curr Med Chem       Date:  2000-12       Impact factor: 4.530

10.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

Authors:  N S Gray; L Wodicka; A M Thunnissen; T C Norman; S Kwon; F H Espinoza; D O Morgan; G Barnes; S LeClerc; L Meijer; S H Kim; D J Lockhart; P G Schultz
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728

View more
  3 in total

1.  Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors.

Authors:  Amany Belal; Nagwa M Abdel Gawad; Ahmed B M Mehany; Mohammed A S Abourehab; Hazem Elkady; Ahmed A Al-Karmalawy; Ahmed S Ismael
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  High-Throughput Screening for Bacterial Glycosyltransferase Inhibitors.

Authors:  Samir El Qaidi; Congrui Zhu; Peter McDonald; Anuradha Roy; Pradip Kumar Maity; Digamber Rane; Chamani Perera; Philip R Hardwidge
Journal:  Front Cell Infect Microbiol       Date:  2018-12-18       Impact factor: 5.293

3.  Novel benzylidene benzofuranone analogues as potential anticancer agents: design, synthesis and in vitro evaluation based on CDK2 inhibition assays.

Authors:  Aravinda Pai; Jayashree B S
Journal:  3 Biotech       Date:  2022-09-02       Impact factor: 2.893

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.